Risankizumab for Ulcerative Colitis-Reply
JAMA
.
2025 Feb 18;333(7):637-638.
doi: 10.1001/jama.2024.25643.
Authors
Edouard Louis
1
,
Jasmina Kalabic
2
,
Edward V Loftus Jr
3
Affiliations
1
Department of Hepato-Gastroenterology and Digestive Oncology, University Hospital CHU of Liège, Liège, Belgium.
2
AbbVie Deutschland GmbH and Co KG, Ludwigshafen, Germany.
3
Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
PMID:
39841446
DOI:
10.1001/jama.2024.25643
No abstract available